Display options
Cite
Morina N, Boçari G, Iljazi A, et al. Maximum Time of the Effect of Antileukotriene - Zileuton in Treatment of Patients with Bronchial Asthma. Acta Inform Med. 2016;24(1):16-9doi: 10.5455/aim.2016.24.16-19.
Morina, N., Boçari, G., Iljazi, A., Hyseini, K., & Halac, G. (2016). Maximum Time of the Effect of Antileukotriene - Zileuton in Treatment of Patients with Bronchial Asthma. Acta informatica medica : AIM : journal of the Society for Medical Informatics of Bosnia & Herzegovina : casopis Drustva za medicinsku informatiku BiH, 24(1), 16-9. https://doi.org/10.5455/aim.2016.24.16-19
Morina, Naim, et al. "Maximum Time of the Effect of Antileukotriene - Zileuton in Treatment of Patients with Bronchial Asthma." Acta informatica medica : AIM : journal of the Society for Medical Informatics of Bosnia & Herzegovina : casopis Drustva za medicinsku informatiku BiH vol. 24,1 (2016): 16-9. doi: https://doi.org/10.5455/aim.2016.24.16-19
Morina N, Boçari G, Iljazi A, Hyseini K, Halac G. Maximum Time of the Effect of Antileukotriene - Zileuton in Treatment of Patients with Bronchial Asthma. Acta Inform Med. 2016 Feb;24(1):16-9. doi: 10.5455/aim.2016.24.16-19. Epub 2016 Feb 02. PMID: 27046942; PMCID: PMC4789724.
Copy Download .nbib Format: NLM
Share it on

Acta Inform Med. 2016 Feb;24(1):16-9. doi: 10.5455/aim.2016.24.16-19. Epub 2016 Feb 02.

Maximum Time of the Effect of Antileukotriene - Zileuton in Treatment of Patients with Bronchial Asthma.

Acta informatica medica : AIM : journal of the Society for Medical Informatics of Bosnia & Herzegovina : casopis Drustva za medicinsku informatiku BiH

Naim Morina, Gëzim Boçari, Ali Iljazi, Kadir Hyseini, Gunay Halac

Affiliations

  1. Department of Pharmacy, Faculty of Medicine. University of Prishtina. Clinical Centre, Mother Theresa Str., Prishtina. Kosova.
  2. Department of Pharmacology, Faculty of Medicine. University of Tirana, Albania.
  3. Kosovo Occupational Health Institute, Clinical Centre N.N., Gjakova, Kosova.
  4. Universe College, Bardhosh, Kosove.

PMID: 27046942 PMCID: PMC4789724 DOI: 10.5455/aim.2016.24.16-19

Abstract

OBJECTIVE: Maximum time of the effect of antileukotriene substances - Zileuton in the treatment of patients with bronchial asthma and increased bronchial reactivity and of the salbutamol as agonist of the beta2 adrenergic receptor studied in this work.

METHODS: Parameters of the lung function are determined with Body plethysmography. Raw and ITGV were registered and specific resistance (SRaw) was calculated. Zileuton (Zyflo, tbl. 600 mg), producer Cornerstone Therapeutics, USA was used in the research.

RESULTS: Results of this research, in patients with bronchial asthma, indicate that antileukotriene substances-Zileuton administered in a dose of 600 mg first day (oral route of administration 4 × 1 tbl.) has not caused significant decrease of the specific resistance of the airways (SRaw) (p value 0.1 > Alpha 0.05), whereas Zileuton administered two days in a row, in a dose of 600 mg (4 × 1 tbl. a day), has caused significant decrease of the specific resistance of the airways (SRaw) (P value 0.03 < Alpha 0.05). Effect of the control with salbutamol (beta2-adrenergic receptor agonist) is efficient in the removal of the increased bronchomotor tone, causing significant decrease of the resistance (Raw), respectively of the specific resistance (SRaw), (p value 0.05 = Alpha 0.05).

CONCLUSION: Formation of leukotrienes depends on the lypoxygenation of the arachidonic acid by 5-lypoxygenase. Zileuton is an active and powerful inhibitor of the activity of 5- lypoxygenase and as such inhibits generation of its products. Consequently, besides inhibition of cys-LTs', zileuton also inhibits the formation of leukotriene B4 (LTB4), which is a powerful chemotactic of other eicosanoids too, which depend on the synthesis of lekotriene A4 (LTA4). This suggests that the effect of antileukotrienes (Zileuton) is not immediate after oral administration, but the powerful effect of the Zileuton seen only after two days of inhibition of cys-LTs', and inhibition of leukotriene B4 (LTB4) and A4 (LTA4).

Keywords: Respiratory system; salbutamol; zileuton

References

  1. J Pharm Pharmacol. 2003 Mar;55(3):279-89 - PubMed
  2. Trends Pharmacol Sci. 1995 Sep;16(9):304-9 - PubMed
  3. J Pharmacol Exp Ther. 1991 Mar;256(3):929-37 - PubMed
  4. Drugs. 2000 Apr;59(4):891-928 - PubMed
  5. Thorax. 2000 Jun;55(6):478-83 - PubMed
  6. Adv Immunol. 2001;77:93-122 - PubMed
  7. Proc Natl Acad Sci U S A. 1979 Sep;76(9):4275-9 - PubMed
  8. Nat New Biol. 1973 Oct 17;245(146):215-7 - PubMed
  9. Eur J Pharmacol. 1995 Mar 6;275(2):207-12 - PubMed
  10. J Pharmacol Exp Ther. 1997 May;281(2):655-62 - PubMed
  11. Am J Respir Crit Care Med. 1998 May;157(5 Pt 1):1381-9 - PubMed
  12. Can J Physiol Pharmacol. 1995 Feb;73(2):191-201 - PubMed

Publication Types